Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world observational study of camrelizumab for inoperable lung cancer
ChiCTR1900026089Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Oct 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in bronchial carcinoma, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Progression-free survival. Planned start Oct 2019; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR1900026089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026089.